Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 5

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 31Gastrointestinal 14Tumor-Agnostic 7Thoracic 6Other solid neoplasm 5Head & Neck 5CNS 4Sarcoma 3Endocrine 3Dermatologic 3Gynecologic 2Breast 2Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1

Conditions

Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 1Carcinoma 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Axitinib × Head & Neck × Clear all
NCT02762513 2021-05-05

Expansion Trial for Axitinib In Head And Neck Cancer

University of Michigan Rogel Cancer Center

Phase 2 Completed
29 enrolled 18 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02857712 2019-08-30

SGC-AX14

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
26 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT01469546 2016-08-29

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

University of Michigan Rogel Cancer Center

Phase 2 Completed
42 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00389441 2013-11-25

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Pfizer

Phase 2 Completed
52 enrolled 9 charts
Head & Neck

Carcinoma, Thyroid Neoplasms

NCT00094055 2012-06-26

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Pfizer

Phase 2 Completed
60 enrolled 9 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡